Non-Coding Rnas Affecting Nlrp3 Inflammasome Pathway in Diabetic Cardiomyopathy: A Comprehensive Review of Potential Therapeutic Options Publisher Pubmed



Radmehr E^{1, 3} ; Yazdanpanah N^{2, 3, 4} ; Rezaei N^{2, 3, 5}
Source: Journal of Translational Medicine Published:2025

Abstract

Cardiomyopathies are a heterogeneous group of disorders that can lead to fulminant heart failure and sudden cardiac death. In recent years, the prevalence of all types of cardiomyopathies has shown an upward trend globally. Up to 40% of patients with cardiomyopathy-related heart failure have diabetes mellitus (DM). With the fast global spread of DM, the prevalence of DCM is increasing accordingly and it remains the leading cause of morbidity and mortality in chronic diabetic patients. NLRP3 inflammasome significantly contributes to the development and pathological progression of DCM. Targeting the inflammasome or any of the mediators along its activation pathway provides new potential therapeutic targets for developing specialized drugs to treat DCM. In this comprehensive review, we sought to introduce and summarize the non-coding RNAs with potential therapeutic effects targeting NLRP3 inflammasome signaling in DCM. We hope this general overview can aid future research in developing new therapies for DCM. © The Author(s) 2025.